Indoco Remedies Ltd.

NSE: INDOCO BSE: 532612 SECTOR: Pharmaceuticals & Drugs  25k   105   10

338.90
-0.10 (-0.03%)
NSE: Today, 03:55 PM

Price Summary

Today's High

₹ 343.35

Today's Low

₹ 331

52 Week High

₹ 429

52 Week Low

₹ 307.65

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

3122.98 Cr.

Enterprise Value

3347.97 Cr.

No. of Shares

9.22 Cr.

P/E

19.97

P/B

3.13

Face Value

₹ 2

Div. Yield

0.66 %

Book Value (TTM)

₹  108.26

CASH

19.21 Cr.

DEBT

244.21 Cr.

Promoter Holding

58.69 %

EPS (TTM)

₹  16.97

Sales Growth

24.14%

ROE

18.47 %

ROCE

23.31%

Profit Growth

67.25 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Indoco Remedies Ltd.

SPADE SURGE-RADIUS WARREN WARREN-EXCEL SPERA

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year24.14%
3 Year16.74%
5 Year7.51%

Profit Growth

1 Year67.25%
3 Year283.47%
5 Year14.81%

ROE%

1 Year18.47%
3 Year11.61%
5 Year8.12%

ROCE %

1 Year23.31%
3 Year14.9%
5 Year10.71%

Debt/Equity

0.27

Price to Cash Flow

17.99

Interest Cover Ratio

14.5542875175718

CFO/PAT (5 Yr. Avg.)

2.04601828467081

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2022 58.69 0
Sep 2022 58.69 0
Jun 2022 58.69 0
Mar 2022 58.69 0
Dec 2021 58.69 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 283.467439228538% for the Past 3 years.
  • The company has shown a good revenue growth of 16.7421297407688% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 14.5542875175718.
  • Company’s PEG ratio is 0.297036306578317.
  • The company has an efficient Cash Conversion Cycle of 27.8574634969016 days.
  • The company has a good cash flow management; CFO/PAT stands at 2.04601828467081.
  • The company has a high promoter holding of 58.69%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 14.3150632068471.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 357.76 408.88 407.9 432.69 398.64
Total Expenditure 284.36 328.41 336.6 344.93 336.99
Operating Profit 73.4 80.47 71.3 87.76 61.65
Other Income 0.16 0.29 1.13 0.34 0.37
Interest 3.81 3.04 4.13 5.25 7.01
Depreciation 19.22 18.04 20.1 15.65 17.16
Exceptional Items 0 0 0 0 0
Profit Before Tax 50.53 59.68 48.2 67.2 37.85
Tax 17.56 19.31 9.73 17.56 9.98
Profit After Tax 32.97 40.37 38.47 49.64 27.87
Adjusted EPS (Rs) 3.58 4.38 4.17 5.39 3.02

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 1038.21 967.73 1105.99 1240.3 1539.72
Total Expenditure 906.73 891.03 985.01 1022.67 1213.81
Operating Profit 131.49 76.7 120.98 217.63 325.91
Other Income 8.15 6.71 4.79 9.05 6.71
Interest 23.51 21.09 26.25 22.22 17.43
Depreciation 67.71 71.56 70.81 73.12 78.95
Exceptional Items 0 0 0 0 0
Profit Before Tax 48.43 -9.24 28.71 131.35 236.23
Tax 7.23 -6.4 4.46 38.96 81.71
Net Profit 41.2 -2.84 24.25 92.39 154.52
Adjusted EPS (Rs.) 4.47 -0.31 2.63 10.03 16.77

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 18.43 18.43 18.43 18.43 18.43
Total Reserves 657.13 642.65 661.73 750.5 885.87
Borrowings 123.28 128.66 96.93 96.94 95.88
Other N/C liabilities 2 -12.31 3.98 61.36 60.68
Current liabilities 416.89 445.33 459.17 408.54 519.93
Total Liabilities 1217.72 1222.76 1240.24 1335.76 1580.8
Assets
Net Block 488.73 467.52 589.62 569.91 554.98
Capital WIP 75.78 141.23 7.32 25.12 52.82
Intangible WIP 59.78 44.2 43.38 42.98 68.72
Investments 2.61 2.44 2.45 2.45 2.46
Loans & Advances 33.58 21.75 26.07 63.95 25.98
Other N/C Assets 20.09 9.11 9.64 9.39 9.83
Current Assets 537.15 536.5 561.76 621.95 866.01
Total Assets 1217.72 1222.76 1240.24 1335.76 1580.8
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 48.43 -9.24 28.71 131.35 236.23
Adjustment 97.82 89.34 99.51 109.71 87.12
Changes in Assets & Liabilities -13.59 55.66 -1.65 -139.14 -108.81
Tax Paid -9.89 -3.62 -3.92 -19.75 -40.99
Operating Cash Flow 122.76 132.13 122.66 82.17 173.55
Investing Cash Flow -135.43 -103.76 -55.95 -66.7 -121.41
Financing Cash Flow -38.77 -16.14 -63.95 -29.83 -44.37
Net Cash Flow -51.44 12.23 2.76 -14.35 7.77

Corporate Actions

Investors Details

PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Promoters 58.69 58.69 58.69 58.69 58.69
spa holdings pvt l... 19.90 19.90 19.90 19.90 19.85
shanteri investmen... 17.12 17.12 17.12 17.12 17.07
panandikar aditi m... 6.03 6.03 6.03 6.03 6.02
ramani madhura anup 5.63 5.63 5.63 5.63 5.61
kare aruna suresh 5.20 5.20 5.20 5.20 5.19
kare suresh govind 4.41 4.41 4.41 4.41 4.40
kare suresh govind... - - - - 0.30
suresh govind kare... - 0.30 0.30 0.30 -
suresh govind kare... 0.30 - - - -
sharda ramnath kare 0.04 0.04 0.04 0.04 0.04
pratima ajit vaidya 0.03 0.03 0.03 0.03 0.03
rohan anup ramani 0.01 0.01 0.01 0.01 0.01
sudha m pai 0.01 0.01 0.01 0.01 0.01
mahika milind pana... 0.01 0.01 0.01 0.01 0.01
milind s panandikar 0.01 - - 0.01 0.01
megh milind panand... 0.01 0.01 0.01 0.01 0.01
milnd s panandikar - 0.01 0.01 - -
PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Investors 41.31 41.31 41.31 41.31 41.31
nippon life india ... 5.52 - - - -
nippon life india ... - - - - 6.20
nippon life india ... - 5.23 4.99 4.99 -
icici prudential p... - - - - 4.82
icici prudential p... 4.77 4.59 4.32 - -
icici prudential p... - - - - -
icici prudential p... - - - - -
icici prudent phar... - - - - -
icici prudential s... - - - 3.93 -
nippon life india ... 2.53 - - - -
aditya birla sun l... 1.59 1.90 2.13 2.20 -
sundaram mutual fu... - - - - -
sundaram mutual fu... - - - - 1.30
franklin india sma... - - 1.10 1.32 -
mangeshi investmen... - 1.27 - 1.27 1.26
mangeshi investmen... - - - - -
mangeshi investmen... 1.27 - - - -
adity birla life t... - - - - 1.23
dsp healthcare fund 1.22 1.22 1.22 1.22 -
aditya birla sun l... - - - - -
aditya birla sun l... - - - - -
sundaram mutual fu... 1.10 - - - -
aditya birla sun l... - - - - -
dsp healthcare ltd - - - - 1.01
llp 0.10 0.11 0.12 0.24 0.06
iinvestor educatio... - - 0.11 - -
iepf 0.11 0.11 - - 0.06
investor education... - - - 0.11 -
body corp ltd liab... - - - - -
independent direct... - - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Indoco Remedies informs about press release25 Jan 2023, 4:32PM Indoco Remedies reports 15% drop in Q3 consolidated net profit25 Jan 2023, 12:37PM Indoco Remedies informs about audio recording of earnings call 25 Jan 2023, 11:51AM Indoco Remedies informs about outcome of board meeting 24 Jan 2023, 2:48PM Indoco Remedies - Quaterly Results24 Jan 2023, 12:07PM Indoco Remedies - Quaterly Results24 Jan 2023, 12:07PM Indoco Remedies - Quaterly Results24 Jan 2023, 12:07PM USFDA conducts GMP inspection at Indoco Remedies’ Solid Oral Formulation Facility in Goa23 Jan 2023, 12:30PM Indoco Remedies informs about disclosure of related party transactions 24 Nov 2022, 2:55PM Indoco Remedies - Quaterly Results10 Nov 2022, 11:38AM Indoco Remedies - Quaterly Results10 Nov 2022, 11:38AM Indoco Remedies - Quaterly Results10 Nov 2022, 11:38AM Indoco Remedies informs about revised schedule of con-call meeting8 Nov 2022, 12:12PM Indoco Remedies informs about analyst meet6 Oct 2022, 12:07PM Indoco Remedies’ AnaCipher CRO clears USFDA inspection with Zero 483s 19 Sep 2022, 11:27AM Indoco Remedies informs about annual report26 Aug 2022, 10:11AM Indoco Remedies to acquire stake in Kanakal Wind Energy 17 Aug 2022, 11:17AM Indoco Remedies to acquire up to 26% stake in Jalansar Wind Energy17 Aug 2022, 9:46AM Indoco Remedies informs about audio recording 10 Aug 2022, 9:44AM Indoco Remedies informs about loss of share certificates9 Aug 2022, 4:39PM Indoco Remedies - Quaterly Results9 Aug 2022, 11:35AM Indoco Remedies - Quaterly Results9 Aug 2022, 11:35AM Indoco Remedies - Quaterly Results9 Aug 2022, 11:35AM Indoco Remedies informs about conference call23 Jul 2022, 9:42AM USFDA concludes inspection at Indoco Remedies’ Clinical Research Organization22 Jul 2022, 11:21AM Indoco Remedies informs about analyst meet19 Jul 2022, 12:36PM Indoco Remedies informs about board meeting 15 Jul 2022, 1:32PM Indoco Remedies informs about certificate7 Jul 2022, 12:36PM Indoco Remedies informs about analyst meet15 Jun 2022, 11:42AM Indoco Remedies informs about incorporation of a wholly owned subsidiary company8 Jun 2022, 11:56AM Indoco Remedies incorporates wholly owned subsidiary company8 Jun 2022, 11:28AM Indoco Remedies informs about link of the audio call recording18 May 2022, 12:13PM Indoco Remedies informs about appointment of statutory auditors17 May 2022, 4:46PM Indoco Remedies informs about dividend updates17 May 2022, 4:40PM Indoco Remedies reports 62% rise in Q4 consolidated net profit17 May 2022, 4:30PM Indoco Remedies - Quaterly Results17 May 2022, 12:34PM Indoco Remedies - Quaterly Results17 May 2022, 12:34PM Indoco Remedies - Quaterly Results17 May 2022, 12:34PM Indoco Remedies informs about disclosure23 Apr 2022, 10:28AM Indoco Remedies informs about board meeting22 Apr 2022, 5:14PM Indoco Remedies gets USFDA’s approval for Lacosamide Injection8 Apr 2022, 12:05PM Indoco Remedies receives USFDA’s approval for Lacosamide Tablets22 Mar 2022, 10:44AM Indoco Remedies informs about press release22 Mar 2022, 10:22AM Indoco Remedies incorporates wholly owned subsidiary company in UK 16 Feb 2022, 2:41PM Indoco Remedies informs about analyst meet15 Feb 2022, 2:59PM Indoco Remedies reports 30% rise in Q3 consolidated net profit1 Feb 2022, 3:28PM Indoco Remedies - Quaterly Results1 Feb 2022, 11:40AM Indoco Remedies - Quaterly Results1 Feb 2022, 11:40AM Indoco Remedies - Quaterly Results1 Feb 2022, 11:40AM Indoco Remedies informs about rescheduled conference call29 Jan 2022, 2:38PM

Indoco Remedies Stock Price Analysis and Quick Research Report. Is Indoco Remedies an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Indoco Remedies and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 173.5523 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Indoco Remedies has a Debt to Equity ratio of 0.27 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Indoco Remedies , the EPS growth was 67.2458159621791 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Indoco Remedies has OPM of 21.1666088746124 % which is a good sign for profitability.
     
  • ROE: Indoco Remedies have a average ROE of 18.4698273608014 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Indoco Remedies

X